Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) reached a new 52-week high on Friday . The stock traded as high as $131.59 and last traded at $131.06, with a volume of 299,394 shares changing hands. The stock had previously closed at $130.91.

Several analysts recently weighed in on ZBH shares. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Saturday, April 30th. Morgan Stanley reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Saturday, April 30th. Barclays PLC reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Saturday, April 30th. Canaccord Genuity reiterated a “buy” rating and issued a $150.00 price target on shares of Zimmer Biomet Holdings in a report on Thursday, April 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $134.00 price target (up previously from $129.00) on shares of Zimmer Biomet Holdings in a report on Thursday, April 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twenty have given a buy rating to the company’s stock. Zimmer Biomet Holdings has an average rating of “Buy” and an average target price of $130.45.

The company has a market capitalization of $26.20 billion and a P/E ratio of 120.00. The stock’s 50-day moving average price is $123.61 and its 200 day moving average price is $111.88.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 28th. The company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.97 by $0.05. The business earned $1.93 billion during the quarter, compared to analyst estimates of $1.90 billion. During the same period in the prior year, the business posted $1.58 EPS. Zimmer Biomet Holdings’s revenue was up 65.6% compared to the same quarter last year. Analysts predict that Zimmer Biomet Holdings Inc. will post $7.97 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 29th. Stockholders of record on Friday, June 24th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.73%. The ex-dividend date was Wednesday, June 22nd.

In other news, CAO Tony W. Collins sold 3,611 shares of the firm’s stock in a transaction dated Tuesday, June 14th. The stock was sold at an average price of $116.43, for a total value of $420,428.73. Following the completion of the transaction, the chief accounting officer now directly owns 3,245 shares in the company, valued at $377,815.35. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Daniel P. Florin sold 15,000 shares of the firm’s stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $124.98, for a total value of $1,874,700.00. Following the completion of the transaction, the chief financial officer now owns 16,983 shares of the company’s stock, valued at $2,122,535.34. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have recently made changes to their positions in ZBH. Liberty Mutual Group Asset Management Inc. purchased a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $1,029,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $1,147,000. Mutual of America Capital Management LLC purchased a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $2,669,000. Morgan Stanley boosted its position in shares of Zimmer Biomet Holdings by 21.9% in the fourth quarter. Morgan Stanley now owns 345,535 shares of the company’s stock valued at $35,450,000 after buying an additional 62,101 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. purchased a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $3,844,000.

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.